

Table of Contents

List of abbreviations / 9

Introduction

1. The genesis and importance of the impact of intellectual property protection at the World Trade Organization on access to medicinal products / 11
2. Objectives, methodological assumptions, and book structure / 20

Chapter One

Standards for the protection of medicinal products in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) / 23

1. Genesis of the TRIPS Agreement / 23
 - 1.1. Antecedents / 23
 - 1.2. The General Agreement on Tariffs and Trade (GATT) / 26
 - 1.3. The Uruguay Round of the GATT / 33
2. General characteristics of the TRIPS Agreement / 38
 - 2.1. The nature of the TRIPS Agreement and its relationship with other international agreements / 38
 - 2.2. Principles of intellectual property protection / 41
3. Patent protection / 43
 - 3.1. Subject matter of patent protection / 43
 - 3.1.1. Rationale for patentability / 43
 - 3.1.2. Prohibition of discrimination / 46
 - 3.2. Scope of patent rights / 48
 - 3.2.1. Rights to a product / 49
 - 3.2.2. Rights to a process / 50
 - 3.3. Time period of protection / 50
 - 3.3.1. Minimum period of patent protection / 50
 - 3.3.2. Protection of existing subjects of rights / 52

4. Protection of undisclosed information / 56
5. Trademark protection in the context of border control measures / 60
6. Summary / 66

Chapter Two

Measures for increasing access to medicinal products as part of the World Trade Organization system of intellectual property protection / 69

1. Introductory remarks / 69
2. Flexibilities – concept and attempt at classification / 70
3. The importance of the interpretation and implementation of the TRIPS Agreement / 73
 - 3.1. General comments / 73
 - 3.2. Problems of developing countries – Declaration on the TRIPS Agreement and Public Health / 79
 - 3.2.1. Antecedents / 79
 - 3.2.2. Declaration text / 85
 - 3.2.3. Assessment attempt / 92
4. Exclusion from patentability / 94
5. Fair use of others' inventions / 95
 - 5.1. General comments / 95
 - 5.2. The Canada – Patent Protection of Pharmaceutical Products (DS114) dispute / 96
 - 5.2.1. Dispute background / 97
 - 5.2.2. Dispute parties' positions / 99
 - 5.2.3. Report of the Panel / 103
 - 5.2.4. Concluding remarks / 108
6. Compulsory licensing / 109
 - 6.1. General comments / 109
 - 6.2. Reasons and conditions for issuing compulsory licenses / 112
 - 6.3. The problem of insufficient manufacturing capacities / 121
 - 6.3.1. Problem outline / 121
 - 6.3.2. Course of negotiations / 122
 - 6.3.3. Decision of the General Council of August 30, 2003 / 127
 - 6.3.4. Assessment attempt / 133
 - 6.4. Concluding remarks / 136

7. Parallel import	/ 137
8. Delaying the obligation to implement the treaty regulations	/ 142
9. The role of other international organizations	/ 144
10. Practical possibilities to promote access to medicinal products: the case of India	/ 148
11. Summary	/ 153
Chapter Three	
Agreements going beyond the standards of the TRIPS Agreement	/ 157
1. The TRIPS Agreement as a minimum standard of protection	/ 157
2. Bilateral agreements liberalizing trade and investment protection	/ 158
3. Agreements of universal scope of application	/ 163
3.1. The Anti-Counterfeiting Trade Agreement (ACTA)	/ 163
3.2. Trans-Pacific Partnership Agreement (TPP)	/ 167
4. Summary	/ 168
Chapter Four	
Access to medicinal products as a component of the right to health	/ 171
1. Intellectual property rights and human rights – conflict or convergence?	/ 171
2. The right to health in international human rights law	/ 175
3. Obligations of countries to ensure access to medicinal products	/ 180
4. The right to health within the World Trade Organization system	/ 187
5. Summary	/ 192
Conclusions	/ 197
Bibliography	/ 199